Stille W, Helm E, Kilp W
Department of Internal Medicine, University of Frankfurt-on-Main, West Germany.
Proc R Soc Med. 1977;70 Suppl 1(Suppl 1):40-2. doi: 10.1177/00359157770700S112.
The present study reports on 15 patients with confirmed or suspected secondary fungal infection, who were treated with intravenous miconazole and a daily dose of 0.4 to 28 g (mean 9.8 g). The mycological findings confirmed infection with Aspergillus fumigatus in 6 patients and severe infection with Candida albicans in 4. Clinically mycological cures were achieved in 4 patients and some improvement was found in 3 others. The excellent patient tolerance of the drug makes it seem a likely treatment not only for patients with mycologically confirmed infection but also for those whose condition exposes them to a high risk of fungal infection.
本研究报告了15例确诊或疑似继发性真菌感染的患者，他们接受了静脉注射咪康唑治疗，日剂量为0.4至28克（平均9.8克）。真菌学检查结果证实，6例患者感染烟曲霉，4例患者感染白色念珠菌且病情严重。4例患者实现了临床真菌学治愈，另有3例有一定改善。该药出色的患者耐受性使其似乎不仅适用于真菌学确诊感染的患者，也适用于那些有真菌感染高风险的患者。
